Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers

Urology

Volumn 73, Issue 5 SUPPL., 2009, Pages

  Fleshner, Neil E ^a,b   Lawrentschuk, Nathan ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ADVANCED CANCER; AGING; ARTICLE; CANCER RISK; CANCER SCREENING; ETHNICITY; FAMILY HISTORY; GENETICS; HUMAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RACE DIFFERENCE;

DISEASE SUSCEPTIBILITY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 64349085837     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.022     Document Type: Article

References (48)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
3. Wilson L.S., Tesoro R., Elkin E.P., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007) 518-527
4. Grover S.A., Dorais M., Paradis G., et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. Can Med Assoc J 163 (2000) 1263-1269
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
6. Rosario D.J., Lane J.A., Metcalfe C., et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study. Eur Urol 53 (2008) 777-784
7. Canby-Hagino E., Hernandez J., Brand T.C., et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 70 (2007) 748-752
8. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
9. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
10. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289-294
11. Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58 (2001) 411-416
12. Schröder F.H., Roobol M.J., Andriole G.L., et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 181 (2009) 69-74
13. Grubb III R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102 (2008) 1524-1530
14. Lilja H., Ulmert D., Björk T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 25 (2007) 431-436
15. Catalona W.J. Prostate cancer screening. BJU Int 94 (2004) 964-966
16. Lilja H, Cronin A, Scardino P, et al. Poster 589: a single PSA predicts prostate cancer up to 30 years subsequently, even in men below age 40. Presented at the Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
17. Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 (2007) 2212-2217
18. Ulmert D., Cronin A.M., Bjork T., et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6 (2008) 6-13
19. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
20. Catalona W.J., Loeb S., and Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 144 (2006) 441-443
21. Ries L., Melbert D., Drapcho M., et al. SEER cancer statistics review. Based on November 2007 SEER data submission, posted to SEER Web site (2008). http://seer.cancer.gov/csr/1975_2005/ Accessed May 30, 2008
22. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
23. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 4 (2000) 267-280
24. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
25. Al-Azab R., Toi A., Lockwood G., et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 69 (2007) 103-107
26. Briganti A., Chun F.K., Suardi N., et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 43 (2007) 2669-2677
27. Sajadi K.P., Kim T., Terris M.K., et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 70 (2007) 691-695
28. Loeb S., Kettermann A., Ferrucci L., et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 54 (2008) 1073-1080
29. Chen Y.C., Page J.H., Chen R., et al. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 68 (2008) 1582-1591
30. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000) 78-85
31. Zheng S.L., Sun J., Wiklund F., et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358 (2008) 910-919
32. Sun J., Chang B.L., Isaacs S.D., et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 68 (2008) 1257-1262
33. Haiman C.A., Patterson N., Freedman M.L., et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39 (2007) 638-644
34. Lefkowitz G.K., Taneja S.S., Brown J., et al. Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 168 4 Pt. 1 (2002) 1415-1418
35. Keetch D.W., Humphrey P., Stahl D., et al. Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 154 2 Pt. 1 (1995) 347-351
36. Bensalah K., Lotan Y., Karam J.A., et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 11 (2008) 112-120
37. Ivanovic V., Melman A., vis-Joseph B., et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1 (1995) 282-284
38. Perry K.T., Anthony C.T., Case T., et al. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49 (1997) 151-155
39. Wolff J.M., Fandel T.H., Borchers H., et al. Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases. Anticancer Res 19 suppl 4A (1999) 2657-2659
40. Michalaki V., Syrigos K., Charles P., et al. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 (2004) 2312-2316
41. Nakashima J., Tachibana M., Horiguchi Y., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
42. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809
43. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
44. Giri V.N., Beebe-Dimmer J., Buyyounouski M., et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 178 (2007) 1920-1924
45. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7 (2005) 60
46. Kirchhoff T., Kauff N.D., and Mitra N. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10 (2004) 2918-2921
47. Leman E.S., Cannon G.W., Trock B.J., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69 (2007) 714-720
48. Leman E., Magheli A., and Cannon G.W. Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract). J Urol 179 (2008) 704